Weiss Ratings Reiterates Sell (D-) Rating for Journey Medical (NASDAQ:DERM)

Key Points

• Weiss Ratings has reaffirmed a "sell (D-)" rating for Journey Medical (NASDAQ: DERM), indicating ongoing concerns about the company's financial health.
• Journey Medical reported earnings per share of ($0.16), missing analysts' estimates, and has a negative return on equity of 48.69%.
• The stock is currently trading at $7.52, with a consensus target price of $12.17 from analysts, reflecting a mix of buy and sell ratings.

Journey Medical (NASDAQ:DERM - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

A number of other equities research analysts have also recently commented on DERM. HC Wainwright began coverage on Journey Medical in a research note on Monday, August 25th. They issued a "buy" rating and a $13.00 target price on the stock. Lake Street Capital increased their target price on Journey Medical from $9.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Zacks Research cut Journey Medical from a "hold" rating to a "strong sell" rating in a research note on Friday, August 15th. Finally, Wall Street Zen cut Journey Medical from a "buy" rating to a "hold" rating in a research note on Sunday, July 6th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $12.17.

Journey Medical Stock Down 0.4%

DERM traded down $0.03 during trading on Wednesday, reaching $7.52. The stock had a trading volume of 158,803 shares, compared to its average volume of 98,948. The stock's 50 day moving average is $7.26 and its two-hundred day moving average is $7.04. The company has a current ratio of 1.27, a quick ratio of 0.95 and a debt-to-equity ratio of 1.11. The company has a market capitalization of $197.85 million, a price-to-earnings ratio of -19.79 and a beta of 0.79. Journey Medical has a one year low of $3.54 and a one year high of $8.90.

Journey Medical (NASDAQ:DERM - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.09). Journey Medical had a negative return on equity of 48.69% and a negative net margin of 15.49%.The firm had revenue of $15.01 million during the quarter, compared to the consensus estimate of $14.93 million. As a group, analysts expect that Journey Medical will post -1.02 earnings per share for the current year.

Institutional Investors Weigh In On Journey Medical

Several institutional investors have recently modified their holdings of DERM. Cambridge Investment Research Advisors Inc. boosted its position in shares of Journey Medical by 3.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 338,050 shares of the company's stock valued at $1,994,000 after buying an additional 9,938 shares during the last quarter. Pale Fire Capital SE bought a new position in Journey Medical in the first quarter valued at about $161,000. Titleist Asset Management LLC lifted its holdings in Journey Medical by 18.3% in the first quarter. Titleist Asset Management LLC now owns 12,900 shares of the company's stock valued at $76,000 after acquiring an additional 2,000 shares during the period. Jane Street Group LLC bought a new position in Journey Medical in the first quarter valued at about $110,000. Finally, Focus Partners Advisor Solutions LLC bought a new position in Journey Medical in the second quarter valued at about $72,000. 7.25% of the stock is owned by hedge funds and other institutional investors.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.